Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cintirorgon + Pembrolizumab in Metastatic NSCLC
NCT03396497Phase 1Unknown
- Sponsor
- Lycera
- Start
- Aug 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cintirorgon, sponsored by Lycera. Primary endpoints: Number of subjects with any treatment-emergent Adverse Events at 12 weeks and Dose Limiting Toxicity. Status: unknown.
02
Drugs
cintirorgon
Beyond the preview
Go deeper on NCT03396497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396497.